iBio Inc (IBIO)
2.08
-0.02
(-0.95%)
USD |
NYAM |
Mar 31, 16:00
2.10
+0.02
(+0.96%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 25.73M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -80.57% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.367 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.76% |
News
Headline
Wire
Time (ET)
PR Newswire
03/03 10:51
PR Newswire
02/21 10:58
PR Newswire
02/17 08:36
SA Breaking News
02/16 18:12
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/12/2023* | 16:30 EST | Earnings Call | Q3 2023 | -- | -- | -- | |
| 05/12/2023* | -- | Results | Q3 2023 | -- | -- | -- | |
| 09/27/2022 | -- | Results | Q4 2022 | -5.63 | -1.75 | -221.7% | |
| 09/27/2022 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 05/12/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 05/12/2022 | -- | Results | Q3 2022 | -1.50 | -1.38 | -9.09% | |
| 02/14/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 02/14/2022 | -- | Results | Q2 2022 | -1.25 | -1.00 | -25.00% |
*Estimated Date/Time
Earnings
Profile
| iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO. |
| URL | https://www.ibioinc.com |
| Investor Relations URL | https://ir.ibioinc.com/ |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Sep. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 31, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 49.29M |
| Net Income (TTM) | -81.13M |
| Total Assets (Quarterly) | 51.80M |
| Total Liabilities (Quarterly) | 32.98M |
| Shareholders Equity (Quarterly) | 18.82M |
| Cash from Operations (TTM) | -39.04M |
| Cash from Investing (TTM) | -0.232M |
| Cash from Financing (TTM) | -1.923M |
Ratings
Profile
| iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO. |
| URL | https://www.ibioinc.com |
| Investor Relations URL | https://ir.ibioinc.com/ |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Sep. 27, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| IBIO Tweets |